

FORM PTO-1449 (Modified)
Approved for use through 1999 12002

US DEPARTMENT OF COMMERCE Docket No.

US Patent and Trademark Office

Docket No. 50623.370 Application No. 10/772,858
Applicant

INFORMATION DISCLOSURE CITATION in an Application

(Use several sheets if necessary)

Syed F.A. Hossainy

Filing Date February 4, 2004 Group Art Unit 1762

U.S. PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate	
Ecc	A1	3,288,052	11/29/66	Hough	99	235		
	A2	4,148,932	4/10/79	Tada et al.	427	31		
	АЗ	4,275,838	6/30/81	Fangmeyer	239	223		
	A4	4,329,383	5/11/82	Joh	428	36	•	
	A5	4,589,597	5/20/86	Robisch et al.	239	703	•	
	A6	4,684,064	8/4/87	Kwok	239	223		
	A7	4,733,665	. 3/29/88	Palmaz	128	343		
	A8	4,795,095	1/3/89	Shepard	239	214.17		
	A9	4,800,882	1/31/89	Gianturco	128	343		
	A10	4,882,168	11/21/89	Casey et al.	424	468		
	A11	4,886,062	12/12/89	Wiktor	128	343	· · · · · · · · · · · · · · · · · · ·	
	A12	4,927,081	5/22/90	Kwok et al.	239	223		
	A13	4,941,870	7/17/90	Okada et al.	600	36	······································	
	A14	4,977,901	. 12/18/90	Ofstead	128	772		
	A15	5,112,457	5/12/92	Marchant	204	165		
	A16	5,165,919	11/24/92	Sasaki et al.	424	488		
	A17	5,272,012	12/21/93	Opolski	428	423.1		
	A18	5,292,516	3/8/94	Viegas et al.	424	423		
	A19	5,298,260	3/29/94	Viegas et al.	424	486		
	A20	5,300,295	4/5/94	Viegas et al.	424	427		
	A21	5,306,501	4/26/94	Viegas et al.	424	423		
	A22	5,328,471	7/12/94	Slepian	604	101	·	
	A23	5,330,768	7/19/94	Park et al.	424	501		
	A24	5,380,299	1/10/95	Fearnot et al.	604	265		
	A25	5,399,198	3/21/95	Ghaisas	118	629		
Ecc	A26	5,417,981	5/23/95	Endo et al.	424	486	*	

Ecc	A27	5,447,724	9/5/95	Helmus et al.	424	426	
	A28	5,455,040	10/3/95	Marchant	424	426	
	A29	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	A30	5,464,650	11/7/95	Berg et al.	427	2.30	
	A31	5,569,463	10/29/96	Helmus et al.	424	426	
	A32	5,578,073	11/26/96	Haimovich et al.	623	1	
	A33	5,605,696	2/25/97	Eury et al.	424	423	
	A34	5,609,629	3/11/97	Fearnot et al.	623	1	
	A35	5,624,411	4/29/97	Tuch	604	265	
	A36	5,628,730	5/13/97	Shapland et al.	604	21	
	A37	5,649,977	7/22/97	Campbell	623	1	
	A38	5,658,995	8/19/97	Kohn et al.	525	-432	
	A39	5,667,767	9/16/97	Greff et al.	424	9.411	
	A40	5,670,558	9/23/97	Onishi et al.	523	-112	
	A41 ·	5,679,400	10/21/97	Tuch	427	2.14	
	A42	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A43	5,702,754	12/30/97	Zhong	427	2.12	
	A44	5,716,981	2/10/98	Hunter et al.	514	449	
	A45	5,735,897	4/7/98	Buirge	623	12	
:	A46	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A47	5,776,184	7/7/98	Tuch	623	1	
	A48	5,788,979	8/4/98	Alt et al.	424	426	
	A49	5,800,392	9/1/98	Racchini	604	96	·
	A50	5,820,917	10/13/98	Tuch	427	2.1	
·	A51	5,824,048	10/20/98	Tuch	623	1	
	A52	5,824,049	10/20/98	Ragheb et al.	623	1	15
	A53	5,830,178	11/3/98	Jones et al.	604	49	
	A54	5,837,008	11/17/98	Berg et al.	623	1	
	A55	5,837,313	11/17/98	Ding et al.	427	2.21	·
	A56	5,851,508	12/22/98	Greff et al.	424	9.411	
Ecc	A57	5,858,746	1/12/99	Hubbell et al.	435	177	

Ecc	A58	5,865,814	2/2/99	Tuch	604	265	
	A59	5,869,127	2/9/99	Zhong	427	2.12	
	A60	5,873,904	2/23/99	Ragheb et al.	623	1	
	A61	5,876,433	3/2/99	Lunn	623	1	
	A62	5,877,224	3/2/99	Brocchini et al.	514	772.2	
	A63	5,925,720	7/20/99	Kataoka et al.	525	523	
	A64	5,955,509	9/21/99	Webber et al.	514	772.7	
	A65	5,957,974	9/28/99	Thompson et al.	623	1.13	
	A66	5,971,954	10/26/99	Conway et al.	604	96	
	A67	5,980,928	11/9/99	Terry	424	427	
	A68	5,980,972	11/9/99	Ding	427	2.24	
	A69 .	5,997,517	12/7/99 ·	Whitbourne	604	265	
	A70	6,010,530	1/4/00	Goicoechea	623	1	
	A71	6,015,541	1/18/00	Greff et al.	424	1.25	
	A72	6,033,582	3/7/00	Lee et al.	216	37	
	A73	6,042,875	3/28/00	Ding et al.	427	2.24	
	A74	6,045,864	4/4/00	Lyons et al.	427	255.23	
	A75	6,051,648	4/18/00	Rhee et al.	525	54.1	
	A7.6	6,051,576	4/18/00	Ashton et al.	514	255	
	A77	6,056,993	5/2/00	Leidner et al.	427	2.25	
	A78	6,060,451	5/9/00	DiMaio et al.	514	13	
	A79	6,060,518	5/9/00	Kabanov et al.	514	781	
	A80	6,080,488	6/27/00	Hostettler et al.	428	423.3	
	A81	6,096,070	8/1/00	Ragheb et al.	623	1	
	A82	6,099,562	8/8/00	Ding et al.	623	1.46	
	A83	6,110,188	8/29/00	Narciso, Jr.	606	153	
	A84	6,110,483	8/29/00	Whitbourne et al.	424	423	
<u> </u>	A85	6,113,629	9/5/00	Ken	623	1.1	
	A86	6,120,536	9/19/00	Ding et al.	623	1.43	
	A87	6,120,904	9/19/00	Hostettler et al.	428	423.3	
	A88	6,121,027	9/19/00	Clapper et al.	435	180	
Ecc	A89	6,129,761	10/10/00	Hubbell .	623	11	

				Τ		T		
3	cc	A90	6,153,252	11/28/00	Hossainy et al.	427	2.3	
_		A91	6,165,212	12/26/00	Dereume et al.	623	1.13	
		A92	6,189,804	2/20/01	Vetter et al.	239	7	
	1.	A93	6,203,551	3/20/01	Wu '	606	108	10/4/99
	<u> </u>	A94	6,231,600.	5/15/01	Zhong	623	1.42	5/26/99
		A95	6,240,616	6/5/01	Yan	29	527.2	4/15/97
		A96	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
		A97	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
		A98	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
		A99	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
		A100	6,267,073	7/31/01	Busse et al.	118	24	9/2/98
		A101	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
		A102	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
		A103	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
		A104	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
		A105	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	\	A106	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
		A107	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
		A108	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	<u> </u>	A109	6,346,110	2/12/02	Wu .	606	108	1/3/01
		A110	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
		A111	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
		A112	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
		A113	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
		A114	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
		A115	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
		A116	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
		A117	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
غ	cc	A118	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00

<u>ε</u> σ	C A119	6,527,801	3/4/03	Dutta	623	1.46	4/1:	3/00
	A120	6,527,863	3/4/03	Pacetti et al.	118	500	6/29	9/01
	A121	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/2	8/00
	A122	6,544,223	4/8/03	Kokish	604	103.01	1/5	/01
	A123	6,544,543	4/8/03	Mandrusov et al.	424	422	12/2	7/00
	A124	6,544,582	4/8/03	Yoe	427	2.24	1/5	/01
	A125	6,555,157	4/29/03	Hossainy	427	2.24	7/25	5/00
	A126	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/2	6/00
	A127	6,565,659	5/20/03	Pacetti et al.	118	500	6/28	3/01
	A128	6,572,644	6/3/03	Moein	623	· 1.11	6/27	7/01
	A129	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29	/00
	A130	6,585,926	7/1/03	Mirzaee	264	400	8/31	/00
80	A131	6,605,154	8/12/03	Villareal	118	500	5/31	/01
		U.S. PATE	NT APPLICATI	ON PUBLICATION DOCUM	IENTS		ı	
Examin Initial			Date of Publication	Name	Class	Subclass	Filing (
80	C A132		8/30/01	Chen et al.	523	121	12/28	
Ea	C A133	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21	/01
E c	C A134	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19	9/00
80	ر A135	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17	
50	C A136	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	/01 ·
80	C A137	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	/02
£ 0	C A138	2003/0099712	5/29/03	Jayaraman	424	486	11/26	5/01
Eve-1		_		TENT DOCUMENTS				
Examine Initial		Document Number	Date of	Country	Class	Subclass	Transla	
	e B1	EP 0 301 856	Publication 2/1/89	European			Yes	No
Ec	C B2	EP 0 514 406	11/25/92	European				
	c B3	EP 0 604 022	6/29/94	European				
Ec	C B4	EP 0 623 354	11/9/94	European				
800	B5	EP 0 665 023	8/2/95	European				
Ec	<u>= 86</u>	EP 0 701 802	3/20/96	European				
	C B7	EP 0 716 836	6/19/96	European	-			
an Eranci	eco/12eene	•						

			T		-1	1	Τ	r
<u> </u>	C 88	EP 0 809 999	12/3/97	European				ļ
	B9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European				
	. B11	EP 0 879 595	11/25/98	European				
	B12	EP 0 910 584	4/28/99	European	_			
	B13	EP 0 923 953	6/23/99	European				
	B14 .	EP 0 953 320	11/3/99	European				
	B15	EP 0 970 711	1/12/00	European				
	B16	EP 0 982 041	3/1/00	European				
	B17	EP 1 273 314	1/8/03	European				
	B18	2001-190687	7/17/01	Japan (Abstract)			Х	
	B19	WO 91/12846	9/5/91	PCT				
	B20	WO 95/10989	4/27/95	PCT				
	B21	WO 96/40174	12/19/96	PCT			-	
	B22	WO 97/10011	3/20/97	PCT				
	B23	WO 97/45105	12/4/97	PCT				
	B24	WO 97/46590	12/11/97	PCT				
	B25	WO 98/17331	4/30/98	PCT				
	B26	WO 98/36784	8/27/98	PCT				
	B27	WO 99/01118	1/14/99	PCT	-			
	B28	WO 99/38546	8/5/99	PCT				
	B29	WO 99/63981	12/16/99	PCT				
	B30	WO 00/02599	1/20/00	PCT		-		
	B31	WO 00/12147	3/9/00	PCT				
	B32	WO 00/18446	4/6/00	PCT				
	B33	WO 00/64506	11/2/00	PCT			· ·	
	B34	WO 01/01890	1/11/01	PCT				
	B35	WO 01/15751	3/8/01	PCT				
	B36	WO 01/17577	3/15/01	PÇT				
\bot	B37	WO 01/45763	6/28/01	PCT				
ECC	B38	WO 01/49338	7/12/01	PCT				

			T		·				
<u>ε</u>	ÇC	B39	WO 01/74414	10/11/01	PCT	<u> </u>			
	1.	B40	WO 02/03890	1/17/02	PCT				
		B41	WO 02/026162	4/4/02	PCT				
		B42	WO 02/34311	5/2/02	PCT				
		B43	WO 02/056790	7/25/02	PCT				
		B44	WO 03/000308	1/3/03	PCT	-			
	I^-	B45	WO 03/022323	3/20/03	PCT	-			
		B46	WO 03/028780	4/10/03	PCT				
		B47	WO 03/037223	5/8/03	, PCT		-		-
5 6		B48	WO 03/039612	5/15/03	PCT				
			OTHER DO	CUMENTS (Incl	luding Author, Title, Date, Pertinent P	ages, etc.)			1.
E	ce	C1	Anonymous, Cardiolo	gists Draw - Up T	he Dream Stent, Clinica 710:15 (J ht?req=1061848202959, printed 8	lune 17, 19			
		C2	Anonymous, <i>Heparin</i> http://www.dialogweb	coated stents cut com/cgi/documen	complications by 30%, Clinica 73 st?req=1061847871753, printed 8	2:17 (Nov. /25/03 (2 p	18, 1996 ages).),	
.]		СЗ	Anonymous, <i>Rolling</i> (Abstract 434009), Re		Loading Device for Therapeutic A 4-975 (June 2000).	Agent Deliv	ery or Co	ated St	ent
		C4			inate cardiology, Clinica 720:22 (\$ st?req=1061848017752, printed 8				
		C5		tion of cross-linke	d aliphatic polyester and applicati			sive ma	ateria
		C6		se of Antitumor Ag	ents Prevents Smooth Muscle Ce	ell Prolifera	tion After	Endoth	elial
		C7		ng of commercially	available materials with a new he	eparinizable	e materia	, J. Bio	med.
1		C8		re segment desigi	n for drug delivery control of them	no-respons	ive polym	eric mi	celles
		C9	Dev et al., Kinetics of	Drug Delivery to t	he Arterial Wall Via Polyurethane eterization and Cardiovascular Di	-Coated Re	emovable	Nitinol	Stent
		C10		of Intravascular S	Stents with Genetically Engineered		_		
		C11	Eigler et al., Local Art	erial Wall Drug De	livery from a Polymer Coated Rei	movable M	etallic Ste	ent: Kine	etics,
		C12	Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994). Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).						
		C13			atings: Taxol and Related Compo		in. Interve	ent. Car	diol.
		C14	Inoue et al., An AB blo	ock copolymer of c	oligo(methyl methacrylate) and po of Controlled Release 51:221-229	ly(acrylic a (1998)	cid) for m	icellar	
		C15			s as vehicles for drug delivery, Jo		entrolled F	Release	
23	20	C16	Levy et al., Strategies	For Treating Arter	rial Restenosis Using Polymeric Chem. Soc. Symp.], pp. 259-268 (1	Controlled F	Release Ir	nplants)

Ecc	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p 321 (P1694), Abstr. Suppl. (1993).
	C23	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998)
	C24	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C25	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C26	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
	C27	Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).
	C28	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
	C29	Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).
Ecc	C30	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).
XAMINER	ε	RMA CAMERON DATE CONSIDERED 9/6/05
CAMINER: Initial land in the court of the co	tial if refe this form	erences considered, whether or not citation is in conformance with MPEP § 609; Oraw line through citation if not in conformance and not considered. with next communication to applicant.